
Cingulate shares plans to resubmit its ADHD candidate CTx-1301 to the FDA, following a CRL tied to CMC information requests
Strategies to reduce aggression in psychiatric treatment settings.
View the slides in PDF format. Also see: Violence in Bipolar Disorder.






